XML 116 R75.htm IDEA: XBRL DOCUMENT
v3.23.2

Collaboration Agreement - Additional Information (Details) - License and Collaboration Agreement - Astellas Pharma LLC - USD ($) $ in Thousands | 1 Months Ended | 3 Months Ended | 6 Months Ended | 12 Months Ended
--- | --- | --- | --- | ---
Jul. 31, 2019 | Mar. 31, 2023 | Mar. 31, 2022 | Jun. 30, 2021 | Dec. 31, 2022 | Dec. 31, 2021
Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items] |  |  |  |  |  |
Payments received under collaboration agreement | $ 80,000 |  |  |  |  |
Agreement termination notice period | 60 days |  |  |  |  |
Right to terminate agreement if breach remains uncured | 90 days |  |  |  |  |
Right to terminate agreement incase of nonpayment | 45 days |  |  |  |  |
Transaction price allocated to single combined performance obligation |  |  |  | $ 80,000 |  |
Upfront fee recognized as revenue | $ 80,000 |  |  |  |  |
joint cost |  | $ 14 | $ 193 |  | $ 392 | $ 885
Phase 2b Clinical Trial | Europe |  |  |  |  |  |
Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items] |  |  |  |  |  |
Revenue recognized potential development milestone payments to receive | 65,000 |  |  |  |  |
Phase 2b Clinical Trial | Asia |  |  |  |  |  |
Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items] |  |  |  |  |  |
Revenue recognized potential development milestone payments to receive | 25,000 |  |  |  |  |
Phase 3 Clinical Trial | Europe |  |  |  |  |  |
Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items] |  |  |  |  |  |
Revenue recognized potential development milestone payments to receive | 100,000 |  |  |  |  |
Phase 3 Clinical Trial | Asia |  |  |  |  |  |
Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items] |  |  |  |  |  |
Revenue recognized potential development milestone payments to receive | 40,000 |  |  |  |  |
Maximum |  |  |  |  |  |
Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items] |  |  |  |  |  |
Revenue recognized potential development milestone payments to receive | 230,000 |  |  |  |  |
Revenue recognized commercialization milestone payments to receive | 315,000 |  |  |  |  |
Potential commercial milestone payments eligible to receive upon successful commercialization | $ 315,000 |  |  |  |  |

X
- Definition Agreement termination notice period. + References No definition available. + Details
Name: | freq_AgreementTerminationNoticePeriod
Namespace Prefix: | freq_
Data Type: | xbrli:durationItemType
Balance Type: | na
Period Type: | duration

X
- Definition Contract with customer liability revenue recognized from commercialization milestones. + References No definition available. + Details
Name: | freq_ContractWithCustomerLiabilityRevenueRecognizedFromCommercializationMilestones
Namespace Prefix: | freq_
Data Type: | xbrli:monetaryItemType
Balance Type: | credit
Period Type: | duration

X
- Definition joint cost + References No definition available. + Details
Name: | freq_JointCost
Namespace Prefix: | freq_
Data Type: | xbrli:monetaryItemType
Balance Type: | debit
Period Type: | duration

X
- Definition Revenue recognition potential commercial milestone payments eligible upon successful commercialization. + References No definition available. + Details
Name: | freq_RevenueRecognitionPotentialCommercialMilestonePaymentsEligibleUponSuccessfulCommercialization
Namespace Prefix: | freq_
Data Type: | xbrli:monetaryItemType
Balance Type: | credit
Period Type: | duration

X
- Definition Revenue recognition transaction price. + References No definition available. + Details
Name: | freq_RevenueRecognitionTransactionPrice
Namespace Prefix: | freq_
Data Type: | xbrli:monetaryItemType
Balance Type: | credit
Period Type: | duration

X
- Definition Right to terminate agreement if breach remains uncured. + References No definition available. + Details
Name: | freq_RightToTerminateAgreementIfBreachRemainsUncured
Namespace Prefix: | freq_
Data Type: | xbrli:durationItemType
Balance Type: | na
Period Type: | duration

X
- Definition Right to terminate agreement incase of nonpayment. + References No definition available. + Details
Name: | freq_RightToTerminateAgreementIncaseOfNonpayment
Namespace Prefix: | freq_
Data Type: | xbrli:durationItemType
Balance Type: | na
Period Type: | duration

X
- Definition Upfront fee recognized as revenue. + References No definition available. + Details
Name: | freq_UpfrontFeeRecognizedAsRevenue
Namespace Prefix: | freq_
Data Type: | xbrli:monetaryItemType
Balance Type: | credit
Period Type: | duration

X
- Definition Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table. + References Reference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 808 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Subparagraph (d) -Publisher FASB -URI https://asc.fasb.org//1943274/2147479402/808-10-50-1 + Details
Name: | us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems
Namespace Prefix: | us-gaap_
Data Type: | xbrli:stringItemType
Balance Type: | na
Period Type: | duration

X
- Definition Amount of revenue recognized that was previously included in balance of obligation to transfer good or service to customer for which consideration from customer has been received or is due. + References Reference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 606 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 8 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org//1943274/2147479806/606-10-50-8 + Details
Name: | us-gaap_ContractWithCustomerLiabilityRevenueRecognized
Namespace Prefix: | us-gaap_
Data Type: | xbrli:monetaryItemType
Balance Type: | credit
Period Type: | duration

X
- Definition Cash received from collaborators during the current period. + References Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 230 -SubTopic 10 -Section 45 -Paragraph 25 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org//1943274/2147482740/230-10-45-25 + Details
Name: | us-gaap_ProceedsFromCollaborators
Namespace Prefix: | us-gaap_
Data Type: | xbrli:monetaryItemType
Balance Type: | debit
Period Type: | duration

X
- Details
Name: | us-gaap_TypeOfArrangementAxis=freq_LicenseAndCollaborationAgreementMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | srt_CounterpartyNameAxis=freq_AstellasPharmaLimitedLiabilityCompanyMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis=freq_Phase2bClinicalTrialMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | srt_StatementGeographicalAxis=srt_EuropeMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | srt_StatementGeographicalAxis=srt_AsiaMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis=freq_Phase3ClinicalTrailMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | srt_RangeAxis=srt_MaximumMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |